ArticleMikrochimica acta2026
Detection of unamplified mycobacterium tuberculosis genomic DNA in sputum samples using a metal-enhanced fluorescence-based biosensor.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycobacterium tuberculosis the development of a metal-enhanced fluorescence (MEF)-based biosensor in this study enabled the detection of Mycobacterium tuberculosis DNA extracted from sputum samples with high sensitivity and without the need for DNA amplification. The detection process involved the utilization of silver dendritic nanostructures, which were grown on the surface of silicon wafers and subsequently modified with a probe that was designed to target the specific DNA Insertion Element 6110 (IS6110) gene of M. tuberculosis. A comparison was made between the performance of the developed nanobiosensor and that of other methods, including smear, culture, PCR, and real-time PCR. A total of 385 (including 50 confirmed positive) sputum samples were examined. Of these, 8.8%, 10%, 11.9%, 13%, and 12% cases were confirmed positive by smear, culture, PCR, real-time PCR, and the developed nanobiosensor, respectively. The limit of detection was established at 2.9 × 10
Indexed as
Identifiers
42891697What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.